Immix Biopharma (IMMX) Short Interest Ratio & Short Volume → “Dollar Will Be Worth NOTHING” -Musk (From Crypto 101 Media) (Ad) Free IMMX Stock Alerts $2.25 -0.10 (-4.26%) (As of 05/16/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Immix Biopharma Short Interest DataCurrent Short Volume387,500 sharesPrevious Short Volume349,900 sharesChange Vs. Previous Month+10.75%Dollar Volume Sold Short$840,875.00Short Interest Ratio / Days to Cover1.9Last Record DateApril 30, 2024Outstanding Shares26,410,000 sharesFloat Size13,850,000 sharesShort Percent of Float2.80%Today's Trading Volume53,852 sharesAverage Trading Volume234,872 sharesToday's Volume Vs. Average23% Short Selling Immix Biopharma ? Sign up to receive the latest short interest report for Immix Biopharma and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatIMMX Short Interest Over TimeIMMX Days to Cover Over TimeIMMX Percentage of Float Shorted Over Time Ad Crypto 101 MediaA ‘DeFi Summer’ Projected!Top analysts are predicting DeFi coins to see massive gains in the coming months… During this dubbed ‘DeFi Summer…’ A coin that has been called the “DeFi pioneer” is poised to shoot up 3-7x!Just click here to learn how you can access this coin right now. Immix Biopharma Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/30/2024387,500 shares $840,875.00 +10.8%2.8%1.9 $2.17 4/15/2024349,900 shares $930,734.00 -10.0%2.5%1.3 $2.66 3/31/2024388,800 shares $1.19 million +22.8%2.8%1.4 $3.07 3/15/2024316,600 shares $835,824.00 +19.9%3.1%1.1 $2.64 2/29/2024264,100 shares $884,735.00 -14.5%3.5%0.7 $3.35 2/15/2024308,900 shares $898,899.00 -37.0%4.1%0.9 $2.91 Get the Latest News and Ratings for IMMX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Immix Biopharma and its competitors with MarketBeat's FREE daily newsletter. 1/31/2024489,900 shares $1.87 million +123.2%6.4%1.4 $3.82 1/15/2024219,500 shares $1.28 million +3.1%2.9%0.8 $5.81 12/31/2023212,900 shares $1.47 million +52.3%2.8%0.8 $6.92 12/15/2023139,800 shares $1.02 million +0.1%1.8%0.5 $7.27 11/30/2023139,700 shares $713,867.00 -42.4%1.9%0.6 $5.11 11/15/2023242,600 shares $1.08 million -17.8%3.2%1.1 $4.46 10/31/2023295,000 shares $1.07 million +71.3%3.9%1.4 $3.62 10/15/2023172,200 shares $514,017.00 +71.7%2.3%0.9 $2.99 9/30/2023100,300 shares $343,026.00 +39.5%2.0%0.5 $3.42 9/15/202371,900 shares $191,973.00 -33.4%1.7%0.5 $2.67 8/31/2023107,900 shares $219,037.00 +65.0%2.5%0.8 $2.03 8/15/202365,400 shares $121,644.00 +10.3%0.9%0.4 $1.86 7/31/202359,300 shares $122,158.00 +8.2%1.0%0.2 $2.06 7/15/202354,800 shares $125,492.00 -45.0%0.9%0.2 $2.29 6/30/202399,600 shares $267,924.00 -46.1%1.7%0.3 $2.69 6/15/2023184,700 shares $435,892.00 -16.2%3.1%0.6 $2.36 5/31/2023220,300 shares $445,006.00 +43.8%4.2%0.7 $2.02 5/15/2023153,200 shares $315,592.00 -30.8%2.9%0.5 $2.06 4/30/2023221,300 shares $546,611.00 +86.8%4.0%1.1 $2.47 4/15/2023118,500 shares $213,501.45 -23.1%2.1%1.2 $1.80 3/31/2023154,100 shares $280,462.00 +5.2%2.8%1.4 $1.82 3/15/2023146,500 shares $276,885.00 +24.3%2.5%0.8 $1.89 2/28/2023117,900 shares $245,232.00 +20.7%2.0%0.1 $2.08 2/15/202397,700 shares $225,687.00 -43.0%1.7%0.1 $2.31 1/31/2023171,400 shares $445,640.00 -0.9%2.9%0.1 $2.60 1/15/2023172,900 shares $380,380.00 -19.2%2.9%0.2 $2.20 12/30/2022214,100 shares $490,289.00 +128.3%3.6%0.2 $2.29 12/15/202293,800 shares $184,786.00 +281.3%1.6%0.1 $1.97 11/30/202224,600 shares $29,766.00 +5.1%0.4%0.5 $1.21 11/15/202223,400 shares $24,804.00 -20.1%0.4%0.4 $1.06 10/31/202229,300 shares $29,300.00 +8.1%0.5%0.6 $1.00 10/15/202227,100 shares $32,791.00 +11.1%0.5%0.7 $1.21 9/30/202224,400 shares $33,184.00 -60.5%0.4%0.5 $1.36 9/15/202261,700 shares $106,741.00 +92.8%1.1%0.6 $1.73Invest in the "Trojan Horse" of Alzheimer's Treatment (Ad)This one tiny Micro-Cap is at the forefront of what may be the most significant development in healthcare since the discovery of antibiotics.Click here and learn how you can invest in this incredible opportunity>>> IMMX Short Interest - Frequently Asked Questions What is Immix Biopharma's current short interest? Short interest is the volume of Immix Biopharma shares that have been sold short but have not yet been covered or closed out. As of April 30th, investors have sold 387,500 shares of IMMX short. 2.80% of Immix Biopharma's shares are currently sold short. Learn More on Immix Biopharma's current short interest. What is a good short interest ratio for Immix Biopharma? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. IMMX shares currently have a short interest ratio of 2.0. Learn More on Immix Biopharma's short interest ratio. What is a good short interest percentage for Immix Biopharma? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 2.80% of Immix Biopharma's floating shares are currently sold short. Is Immix Biopharma's short interest increasing or decreasing? Immix Biopharma saw a increase in short interest during the month of April. As of April 30th, there was short interest totaling 387,500 shares, an increase of 10.7% from the previous total of 349,900 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Immix Biopharma's float size? Immix Biopharma currently has issued a total of 26,410,000 shares. Some of Immix Biopharma's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Immix Biopharma currently has a public float of 13,850,000 shares. How does Immix Biopharma's short interest compare to its competitors? 2.80% of Immix Biopharma's shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to Immix Biopharma: Eledon Pharmaceuticals, Inc. (0.14%), Anebulo Pharmaceuticals, Inc. (0.19%), Tiziana Life Sciences Ltd (0.38%), Kezar Life Sciences, Inc. (5.70%), CalciMedica, Inc. (0.93%), Kronos Bio, Inc. (1.71%), Checkpoint Therapeutics, Inc. (11.50%), Carisma Therapeutics, Inc. (9.41%), Eagle Pharmaceuticals, Inc. (10.50%), Equillium, Inc. (1.99%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.98 billion), Occidental Petroleum Co. ($3.35 billion), Charter Communications, Inc. ($3.06 billion), General Motors ($2.88 billion), Moderna, Inc. ($2.32 billion), Tractor Supply ($2.27 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.18 billion), Williams-Sonoma, Inc. ($1.95 billion), and Chesapeake Energy Co. ($1.52 billion). View all of the most shorted stocks. What does it mean to sell short Immix Biopharma stock? Short selling IMMX is an investing strategy that aims to generate trading profit from Immix Biopharma as its price is falling. IMMX shares are trading down $0.10 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Immix Biopharma? A short squeeze for Immix Biopharma occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of IMMX, which in turn drives the price of the stock up even further. How often is Immix Biopharma's short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including IMMX, twice per month. The most recent reporting period available is April, 30 2024. More Short Interest Resources from MarketBeat Related Companies: ELDN Short Interest ANEB Short Interest TLSA Short Interest KZR Short Interest CALC Short Interest KRON Short Interest CKPT Short Interest CARM Short Interest EGRX Short Interest EQ Short Interest Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:IMMX) was last updated on 5/17/2024 by MarketBeat.com Staff From Our PartnersCrypto Pioneer Says: “The last crypto bull market has begun.”InvestorPlaceInvest in the "Trojan Horse" of Alzheimer's TreatmentBehind the Markets348 million Americans lives to END as we know it?The Oxford ClubGold Set to EXPLODE!Gold Safe Exchange[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsHow Biden has already won 2024Porter & CompanyA once-in-a-century investment opportunityStansberry ResearchCharles Payne Demystifies OptionsUnstoppable Prosperity